Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

45.7K
Overview
45.7K
Development of Immunocompetence01:22

Development of Immunocompetence

494
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
494

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vaccination with an HSV-1 virus containing CD-137L reduces herpetic corneal disease when used both prophylactically and therapeutically.

Virus research·2026
Same author

UVB induced reactivation leads to HSV1 in the corneas of virtually all latently infected mice and requires STING to develop corneal disease.

Scientific reports·2024
Same author

UV-B induced HSV-1 reactivation leads to infectious virus in the corneas of virtually all latently infected mice and requires an intact STING to develop herpetic stromal keratitis.

Research square·2023
Same author

Role of NK T cells in transplantation with particular emphasis on corneal transplantation.

Transplant immunology·2022
Same author

CD137 costimulation is associated with reduced herpetic stromal keratitis and with developing normal CD8<sup>+</sup> T cells in trigeminal ganglia.

The Journal of general virology·2022
Same author

Central Nervous System Tuberculosis Presenting With Multiple Ring-Enhancing Lesions: A Diagnostic Challenge.

Cureus·2022
Same journal

Mapping the multigenomic human system: structural asymmetry and interface gaps in host-exogenous biological interactions.

Frontiers in microbiology·2026
Same journal

Bacterial resistance across habitats: from German schools to the International Space Station.

Frontiers in microbiology·2026
Same journal

Correction: Unlocking plant growth-promoting traits of endophytic actinobacteria isolated from <i>Anacyclus pyrethrum</i>, an endemic medicinal plant of the Aguelmam azegza region, Morocco.

Frontiers in microbiology·2026
Same journal

Research progress on <i>Avibacterium paragallinarum</i> and related bacterial and viral diseases in poultry and their mixed infections.

Frontiers in microbiology·2026
Same journal

Development and validation of a quantitative method for the enumeration of <i>Salmonella enterica</i> serovar Infantis from environmental poultry feces based on most probable number approach followed by confirmatory qPCR.

Frontiers in microbiology·2026
Same journal

Multi-omics insights into the microbial and metabolic drivers of regional flavor diversity in Guizhou traditional fermented fish.

Frontiers in microbiology·2026
See all related articles

Related Experiment Video

Updated: Oct 8, 2025

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
06:14

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

6.9K

Developments in Vaccination for Herpes Simplex Virus.

Rohini Krishnan1, Patrick M Stuart1

  • 1Department of Ophthalmology, Saint Louis University School of Medicine, St. Louis, MO, United States.

Frontiers in Microbiology
|December 24, 2021
PubMed
Summary
This summary is machine-generated.

New herpes simplex virus (HSV) vaccines are crucial due to high prevalence and rising drug resistance. This review covers HSV treatment, immunology, and promising vaccine candidates for prevention and therapy.

Keywords:
DNA vaccineherpes simplex virus type 1herpes simplex virus type 2live attenuated vaccinemRNA vaccinesubunit vaccinevaccines

More Related Videos

Recurrent Herpetic Stromal Keratitis in Mice, a Model for Studying Human HSK
07:27

Recurrent Herpetic Stromal Keratitis in Mice, a Model for Studying Human HSK

Published on: December 18, 2012

12.1K
Ex Vivo Infection of Murine Epidermis with Herpes Simplex Virus Type 1
11:56

Ex Vivo Infection of Murine Epidermis with Herpes Simplex Virus Type 1

Published on: August 24, 2015

11.3K

Related Experiment Videos

Last Updated: Oct 8, 2025

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
06:14

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

6.9K
Recurrent Herpetic Stromal Keratitis in Mice, a Model for Studying Human HSK
07:27

Recurrent Herpetic Stromal Keratitis in Mice, a Model for Studying Human HSK

Published on: December 18, 2012

12.1K
Ex Vivo Infection of Murine Epidermis with Herpes Simplex Virus Type 1
11:56

Ex Vivo Infection of Murine Epidermis with Herpes Simplex Virus Type 1

Published on: August 24, 2015

11.3K

Area of Science:

  • Virology
  • Immunology
  • Infectious Diseases

Background:

  • Herpes simplex virus (HSV), encompassing HSV-1 and HSV-2, is a prevalent sexually transmitted infection causing severe neonatal infections and infectious blindness.
  • High global prevalence (HSV-2: 13.2%, HSV-1: 66.6% in ages 15-49 as of 2016) and increasing therapy resistance necessitate novel prevention and management strategies.
  • Current understanding of HSV latency and reactivation presents challenges for vaccine development, with no approved vaccines available.

Purpose of the Study:

  • To review current herpes simplex infection treatment guidelines.
  • To elucidate immunological pathways involved in HSV latency and reactivation.
  • To present an overview of novel prophylactic and therapeutic HSV vaccine candidates in development.

Main Methods:

  • Literature review of current HSV treatment guidelines.
  • Analysis of immunological mechanisms underlying HSV latency and reactivation.
  • Survey of pre-clinical and clinical stage HSV vaccine candidates.

Main Results:

  • No approved HSV vaccines currently exist for prophylaxis or therapy.
  • Promising vaccine candidates are in pre-clinical and clinical development, focusing on preventative, therapeutic, or dual-use applications.
  • Ongoing research aims to overcome immunological challenges associated with HSV latency and reactivation.

Conclusions:

  • Development of effective HSV vaccines is imperative due to high disease burden and treatment resistance.
  • Vaccine strategies are being explored for both prevention and therapy, addressing different stages of HSV infection.
  • Further research into HSV immunology and novel vaccine candidates is critical for future management.